ERBB2 and breast cancer: PGB-0 compounds interact with EGFR and HER2 receptors in molecular docking tests and have exhibited cytotoxic activity against HER2+ breast cancer cells (Utomo et al., 2017); however, poor solubility hinders the development of PGB-0 as a viable drug candidate.